Desacetylcinobufotalin is primarily researched for its potential in cancer therapy. It has shown promising results in inhibiting the growth of various cancer cells, particularly in liver and lung cancers. The compound works by inducing apoptosis, or programmed cell death, in malignant cells, which helps in reducing tumor size and progression. Additionally, it has been studied for its ability to enhance the efficacy of other chemotherapy drugs, making it a candidate for combination therapies. Its role in modulating immune responses is also under investigation, which could open avenues for its use in immunotherapy. Further studies are ongoing to fully understand its mechanisms and optimize its application in clinical settings.